.
.
 

.

 

sitemap Sitemap

       You are here: Home > GMP Oligonucleotdes | English

 

 

  Qualification and Validation


Furthermore, GMP requires proof of the process steps which lead to a product or the result expected from each step. This proof is referred to in the pharmaceutical industry as qualification and validation.

This means:

  • The standard operating procedures (SOPs) lay down precisely which measures are taken to produce and analyse the API

  • An independent examination is conducted to ensure that the APIs are only produced and tested as set out

  • Each production and analysis measure carried out is exactly documented

  • Specifications are set out for each starting material, intermediate product and end product

  • Each machine employed is proven to be qualified, and the production and analysis measures are documented in writing

  • A system is introduced to capture and monitor process changes and deviations

  • A training programme is established for all employees to ensure that every employee understands and correctly adheres to all GMP requirements

These steps demanded significant investment from BioSpring GmbH in terms of space, personnel and time. As our customer, you benefit through the certainty that the APIs produced by BioSpring GmbH meet all GMP requirements and you thereby save time and financial resources when getting your future medications approved.

We were supported in the implementation of the GMP system by Dr Klaus von Jan, Compliance and Regulatory Services, Herrmannstrasse 117, 35037 Marburg. You can find additional information at gmp oligonucleotides www.compliancesystems.de under GMP Consulting.

_________________________
gmp oligonucleotides back

.

 

GMP

BioSpring GMP Oligonucleotides

gmp oligonucleotides GMP certificate gmp oligonucleotides
gmp oligonucleotides Clean room (movie)
gmp oligonucleotides GMP manufacturing
gmp oligonucleotides Good Manufacturing Practice
gmp oligonucleotides Analysis and quality assurance

 

Sanofi and BioSpring cooperate on the field of therapeutic oligonucleotide manufacturing
_________________________
. more (.pdf / 4.3 MB) .

 

 
. . . . .
 
.